|
|
|
|
| LEADER |
03243nam a22005175i 4500 |
| 001 |
978-94-007-1706-0 |
| 003 |
DE-He213 |
| 005 |
20151201051130.0 |
| 007 |
cr nn 008mamaa |
| 008 |
110907s2012 ne | s |||| 0|eng d |
| 020 |
|
|
|a 9789400717060
|9 978-94-007-1706-0
|
| 024 |
7 |
|
|a 10.1007/978-94-007-1706-0
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 614.5999
|2 23
|
| 245 |
1 |
0 |
|a Tumors of the Central Nervous System, Volume 4
|h [electronic resource] :
|b Brain Tumors (Part 2) /
|c edited by M.A. Hayat.
|
| 264 |
|
1 |
|a Dordrecht :
|b Springer Netherlands,
|c 2012.
|
| 300 |
|
|
|a XXVI, 386 p.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Tumors of the Central Nervous System ;
|v 4
|
| 520 |
|
|
|a This volume mainly contains information on the diagnosis, therapy, and prognosis of brain tumors. Insights on the understanding of molecular pathways involved in tumor biology are explained, which should lead to the development of effective drugs. Information on pathways (e.g., hedgehog) facilitates targeted therapies in cancer. Tumor models are also presented, which utilize expression data, pathway sensitivity, and genetic abnormalities, representing targets in cancer. For example, rat model of malignant brain tumors using implantation of doxorubicin with drug eluting beads for delivery is explained. The future of pathway-driven therapies for tumors is summarized. The importance of personalizing cancer care is emphasized. The need for supportive measures for survivors of brain cancer is pointed out, so is the quality of life monitoring. The need of rehabilitation therapy for patients with primary and metastatic brain tumors is also emphasized. Role of MicroRNA in distinguishing primary tumors from metastatic primary tumors is discussed. Advantages and limitations of chemotherapy (e.g., temozolomide and doxorubicin) are discussed. The complexity of tumor to tumor transfer is explained; examples discussed are: brain metastases from breast cancer and brain metastases fro non-small cell lung carcinoma. Identification and characterization of biomarkers, including those for metastatic brain tumors, are presented. Genomic analysis for identifying clinically relevant subtypes of glioblastoma is included. A large number of imaging modalities are detailed to study progression and invasion of gliomas.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Neuroradiology.
|
| 650 |
|
0 |
|a Oncology.
|
| 650 |
|
0 |
|a Neurosurgery.
|
| 650 |
|
0 |
|a Pathology.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Cancer Research.
|
| 650 |
2 |
4 |
|a Neuroradiology.
|
| 650 |
2 |
4 |
|a Neurosurgery.
|
| 650 |
2 |
4 |
|a Oncology.
|
| 650 |
2 |
4 |
|a Pathology.
|
| 700 |
1 |
|
|a Hayat, M.A.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9789400717053
|
| 830 |
|
0 |
|a Tumors of the Central Nervous System ;
|v 4
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-94-007-1706-0
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SME
|
| 950 |
|
|
|a Medicine (Springer-11650)
|
